Jason Pitofsky Biography and Net Worth

Jason Pitofsky is the VP of Regeneron Pharmaceuticals.

What is Jason Pitofsky's net worth?: The estimated net worth of Jason Pitofsky is at least $3.14 million as of November 7th, 2025. Pitofsky owns 4,233 shares of Regeneron Pharmaceuticals stock worth more than $3,137,881 as of December 14th. This net worth estimate does not reflect any other assets that Pitofsky may own. Learn More about Jason Pitofsky's net worth.
How do I contact Jason Pitofsky?: The corporate mailing address for Pitofsky and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Jason Pitofsky's contact information.
Has Jason Pitofsky been buying or selling shares of Regeneron Pharmaceuticals?: During the last ninety days, Jason Pitofsky has sold $280,766.33 in Regeneron Pharmaceuticals stock. Most recently, Jason Pitofsky sold 431 shares of the business's stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a transaction totalling $280,766.33. Following the completion of the sale, the vice president now directly owns 4,233 shares of the company's stock, valued at $2,757,503.19. Learn More on Jason Pitofsky's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Jason Pitofsky (VP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 6,931 shares worth more than $4,533,521.33. The most recent insider tranaction occured on November, 7th when VP Jason Pitofsky sold 431 shares worth more than $280,766.33. Insiders at Regeneron Pharmaceuticals own 7.0% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 11/7/2025.

Jason Pitofsky Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/7/2025	Sell	431	$651.43	$280,766.33	4,233
8/7/2024	Sell	487	$1,070.00	$521,090.00	4,204

Jason Pitofsky Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $741.29

$734.38

$746.05

50 Day Range

MA: $664.44

$557.73

$787.32

2 Week Range

Now: $741.29

$476.49

$790.98

Volume

804,824 shs

Average Volume

1,087,883 shs

Market Capitalization

$77.91 billion

P/E Ratio

17.75

Dividend Yield

0.47%

Beta

0.37